Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACA | Q13085 | 13/20 | 0.67 |
| ▸ | PPARD | Q03181 | 5/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.46 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 3/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19834346 | 0.91 | ACACA (0.71) | ACACAPPARDFFAR1ACACB | |
| SCHEMBL19834388 | 0.90 | ACACA (0.69) | ACACAPPARDFFAR1ACACB | |
| SCHEMBL19834450 | 0.86 | ACACA (0.62) | ACACAPPARDFFAR1ACACB | |
| SCHEMBL19405761 | 0.86 | ACACA (0.53) | ACACAP4HTMACACB | |
| SCHEMBL19834495 | 0.82 | ACACA (0.67) | ACACAPPARDFFAR1ACACB | |
| SCHEMBL19834465 | 0.81 | ACACA (0.71) | ACACAPPARDFFAR1ACACB | |
| SCHEMBL19834356 | 0.80 | ACACA (1.00) | ACACAACACB | |
| SCHEMBL19834484 | 0.79 | ACACA (0.71) | ACACAPPARDFFAR1ACACB | |
| SCHEMBL457981 | 0.78 | P4HTM (0.56) | P4HTM | |
| SCHEMBL19834348 | 0.77 | ACACA (0.71) | ACACAACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10252997-B2 | Monocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-09 | — | — | US | disclosed |
| US-20180079723-A1 | MONOCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| EP-3279183-A1 | MONOCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10252997-B2 | Monocyclic compound | FABP1, CPT1A, GOT2 | ACACA 58/4885PPARD 203/4885FFAR1 110/4885 |
| US-20180079723-A1 | MONOCYCLIC COMPOUND | FABP1, CPT1A, GOT2 | ACACA 58/4885PPARD 203/4885FFAR1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.